ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2022)

ARS Pharmaceuticals (SPRY) reported Gains from Investment Securities of $143000.0 for Q4 2022, up 7250.0% sequentially from -$2000.0 in Q2 2022.

ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2022) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 1 years of Gains from Investment Securities data on file, last reported at $143000.0 in Q4 2022.

For the quarter ending Q4 2022, Gains from Investment Securities changed N/A year-over-year to $143000.0; the trailing twelve-month figure through Sep 2023 stood at $143000.0 (changed N/A YoY), and the FY2022 full-year result was $140000.0, up 3600.0% from the prior year.
Gains from Investment Securities rose to $143000.0 in Q4 2022, from -$2000.0 in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $143000.0 in Q4 2022 to a low of -$2000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,042.03 Bn	67,041.74 Bn	-
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.89 Bn	468.10 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.12 Bn	114.87 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.04 Bn	61.29 Bn	3.31 Bn
7	Belite Bio	62.68 Bn	62.68 Bn	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.47 Bn	34.46 Bn	959.66 Mn
10	ARS Pharmaceuticals	559.04 Mn	358.07 Mn	-

Download Data